Pharmanutra Sustainability Profile
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 33 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,270,814 kg CO2e. This figure includes emissions from Scope 1, Scope 2, and Scope 3 sources, with specific contributions of 229,189 kg CO2e from Scope 1, 270,515 kg CO2e from Scope 2, and 771,110 kg CO2e from Scope 3. Notably, the Scope 3 emissions were primarily driven by business travel (684,328 kg CO2e) and employee commuting (86,782 kg CO2e). Pharmanutra's emissions have shown a significant increase from previous years, with total emissions recorded at 256,816 kg CO2e in 2022 and 180,887 kg CO2e in 2021. The company has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The emissions data is not cascaded from any parent organization, indicating that Pharmanutra S.p.A. independently reports its carbon footprint. The company continues to monitor its emissions and is expected to enhance its sustainability efforts in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 39.72 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | - | 000,000 |
How Carbon Intensive is Pharmanutra's Industry?
How Carbon Intensive is Pharmanutra's Location?
Pharmanutra's Scope 3 Categories Breakdown
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 89% of Scope 3 emissions.
Top Scope 3 Categories
Pharmanutra's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmanutra has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
